WO2005063253A1 - Composition medicinale pour le traitement de symptomes allergiques - Google Patents

Composition medicinale pour le traitement de symptomes allergiques Download PDF

Info

Publication number
WO2005063253A1
WO2005063253A1 PCT/JP2004/019227 JP2004019227W WO2005063253A1 WO 2005063253 A1 WO2005063253 A1 WO 2005063253A1 JP 2004019227 W JP2004019227 W JP 2004019227W WO 2005063253 A1 WO2005063253 A1 WO 2005063253A1
Authority
WO
WIPO (PCT)
Prior art keywords
allergic
pharmaceutical composition
rhinitis
composition according
disease
Prior art date
Application number
PCT/JP2004/019227
Other languages
English (en)
Japanese (ja)
Inventor
Michinori Togawa
Akio Yasuda
Original Assignee
Taiho Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co., Ltd. filed Critical Taiho Pharmaceutical Co., Ltd.
Priority to JP2005516607A priority Critical patent/JPWO2005063253A1/ja
Publication of WO2005063253A1 publication Critical patent/WO2005063253A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • composition for treating allergic symptoms comprising
  • the present invention relates to a pharmaceutical composition for preventing or treating various symptoms such as allergic rhinitis, bronchial asthma, allergic skin disease, allergic eye disease, acute rhinitis and sinusitis.
  • allergic diseases represented by allergic rhinitis, bronchial asthma, allergic skin disease, allergic eye disease, etc.
  • antihistamines chemical mediator release inhibitors, Th2 site force-inhibitors are used to improve various symptoms.
  • Drugs leukotriene receptor antagonists, thromboxane A2 receptor antagonists, and steroids.
  • Specific symptoms include runny nose, nasal congestion, and sneezing in allergic rhinitis, wheezing, cough, dyspnea, and kaputum in bronchial asthma.
  • Allergic eye diseases such as rash and redness include itching, conjunctival congestion, and lacrimation.
  • Allergic reactions include an immediate allergic reaction that occurs within 1 hour after the inducing substance serving as an antigen enters the body, and a delayed allergic reaction that occurs several hours after.
  • Delayed-type allergic reactions are persistent nasal congestion in allergic rhinitis, respiratory depression due to nocturnal asthma attacks or allergic inflammation in the respiratory tract in bronchial asthma, and skin rash in allergic skin diseases In pruritus and allergic eye diseases, it is thought to be involved in pruritus and persistent conjunctival hyperemia. It is known that antihistamines having a high effect on the immediate response generally cannot be expected to improve these symptoms.
  • chemical mediator release inhibitors As treatments for the late response, chemical mediator release inhibitors, Th2 site force-in inhibitors, leukotriene receptor antagonists, thromboxane A2 receptor antagonists, steroids, etc. have been used.
  • Sinusitis is caused by inflammation of the mucous membrane of the paranasal sinuses caused by bacteria, fungi, viruses, or allergies, pus and mucus not being discharged, and accumulation in the paranasal sinuses.
  • Ill. Nasal congestion-Headache due to nasal congestion and viscous runny nose are the main symptoms, and antibiotics and decongestants are used as treatments.
  • antibiotics have an effect only when they are caused by bacteria.
  • decongestants have a problem that even if the symptoms are temporarily improved, the symptoms are worsened after long-term use.
  • Acute rhinitis is caused by inflammation of the nasal mucosa by infection with a virus.
  • the main symptoms are sneezing, runny nose, and nasal congestion, which are often seen as a symptom of cold.
  • Antihistamines are known to be effective for sneezing and runny nose. All contain antihistamines.
  • antihistamines are said to have little effect, and even with sympathomimetics combined for the purpose of improving nasal congestion, the effects are not satisfactory.
  • mequitazine phenothiazine
  • mequitazine is a pruritus and allergic substance associated with measles and skin diseases. It is an antihistamine applied to rhinitis and bronchial asthma.
  • mequitazine as a medicinal drug
  • Non-Patent Document 1 it was confirmed that 60% of patients reported complaint when taking mequitazine 3 mg twice a day. Mequitadine has side effects I was not satisfied with it.
  • compositions containing mequitazine and other drugs include rhinitis treatment drugs that contain phenylpropanolamine hydrochloride or hue-refrin hydrochloride and mequitazine or astemizole (Patent Document 1), and tropane alkaloids, which are anticholinergic drugs ,
  • Patent Document 2 A mequitazine-containing preparation in which isopropamide iodide and mequitazine are used in combination (Patent Document 2), a pharmaceutical composition comprising bromhexine or ampoule and ketotifen or mequitazine (Patent Document 3), codin or dihydroco.
  • a pharmaceutical composition containing din and ibuprofen or acetaminophen and ketotifen or mequitazine (Patent Document 4), a composition for treating rhinitis containing a phenothiazine antihistamine such as an anti-inflammatory enzyme drug, an anti-inflammatory drug, and mequitazine ( Patent Document 5), naproxen or diclofenac and carbino The summing or Kurorufue two lamin or Ketochifu E down or pharmaceutical compositions incorporating the mequitazine (Patent Document 6), ⁇ Seto ⁇ amino phen or ephedrine or mequitazine containing oral solid preparation of blending and vitamin B and mequitazine (
  • Patent Document 7 a composition for rhinitis which comprises ketoprofen or isopropylantipyrine and carbinoxamine or chlorphenamine or mequitazine or ketotifen (Patent Document 8) and the like are disclosed.
  • suplatast and! / Or tosil which is a tosylate thereof
  • suplatast and! / Or tosil which is a tosylate thereof
  • Subratast acid is currently used in bronchial asthma, allergic rhinitis and atopic dermatitis as a therapeutic agent for allergic diseases classified as a Th2 site force-in inhibitor.
  • a nasal congestion improving agent comprising a mixture of phenylpropanol hydrochloride or methylephedrine or phenylephrine and suplatast is disclosed (Patent Document 9).
  • Patent Document 10 discloses mequitazine and suplatast as components that can be incorporated into a solid oral pharmaceutical composition for treating rhinitis. Is not even suggested.
  • Patent Document 1 JP-A-07-188002
  • Patent Document 2 Japanese Patent Application Laid-Open No. 08-208483
  • Patent document 3 JP-A-10-45591
  • Patent Document 4 JP-A-10-45595
  • Patent Document 5 JP-A-10-158193
  • Patent Document 6 JP-A-11 255641
  • Patent Document 7 JP-A-2000-169367
  • Patent Document 8 JP 2001-48782 A
  • Patent Document 9 JP 2001-335473 A
  • Patent Document 10 JP-A-2000-95675
  • Non-patent document 1 Otorhinolaryngology perspective, Vol.27, Supple 5, p.579-586, 1984
  • the present invention relates to a side effect for prevention or treatment of various symptoms such as allergic rhinitis, bronchial asthma, allergic skin disease, allergic eye disease, acute rhinitis, sinusitis and the like.
  • ⁇ Provide a pharmaceutical composition.
  • the inventors of the present invention have conducted intensive studies to solve the above-mentioned problems, and as a result, it has been found that, when suplatast is mixed with mequitazine, in particular, an antihistamine, it is possible to effectively suppress a late-type reaction of an allergic reaction. And completed the present invention.
  • the present invention relates to the following (1)-(12).
  • a pharmaceutical composition comprising (1) a combination of (a) mequitazine or a pharmaceutically acceptable salt thereof and (b) splatast or a pharmaceutically acceptable salt thereof as active ingredients.
  • the pharmaceutical composition according to (1) which is used for prevention or treatment of allergic rhinitis, bronchial asthma, allergic skin disease, allergic eye disease, acute rhinitis or sinusitis.
  • the pharmaceutical composition according to (1) which is for preventing or treating nasal obstruction.
  • Component (a) The pharmaceutical composition according to (1), wherein the ratio of the component (b) to 1 part by weight is 10 to 100 parts by weight.
  • component (a) and component (b) are in the same preparation or in the form of separate preparations.
  • a disease due to a late-onset allergic reaction which comprises administering an effective amount of the pharmaceutical composition according to any one of (1) to (1) to a patient having a disease due to late-onset allergic reaction. Prevention or treatment method.
  • a method for preventing or treating nasal congestion comprising administering an effective amount of the pharmaceutical composition according to any one of (1) to (6) to a patient having nasal congestion.
  • the preventive or therapeutic effect on various symptoms such as allergic rhinitis, bronchial asthma, allergic unilateral skin disease, allergic eye disease, acute rhinitis, and sinusitis is enhanced as compared with conventional therapeutic agents.
  • a pharmaceutical composition having few side effects.
  • FIG. 1 is a graph showing the inhibitory effect of late-onset allergic reaction when mequitazine and suplatast tosilate are used.
  • FIG. 2 is a graph showing the inhibitory effect of delayed allergic reaction using diphenhydramine hydrochloride and suplatast tosylate.
  • FIG. 3 is a graph showing the inhibitory effect of late-onset allergic reaction when chlorpheniramine maleate and suplatast tosilate are used.
  • FIG. 4 is a graph showing the inhibitory effect of late-onset allergic reaction when promethazine hydrochloride and suplatast tosilate are used.
  • (a) mequitazine or a pharmaceutically acceptable salt thereof is preferably a free form of mequitazine or an acid addition salt obtained by the action of a pharmaceutically acceptable acid.
  • the acid addition salts include salts with inorganic acids such as hydrochloric acid, sulfuric acid, phosphoric acid, and hydrobromic acid; oxalic acid, maleic acid, fumaric acid, malic acid, tartaric acid, citric acid, benzoic acid, acetic acid, and lactic acid. Salts with organic acids such as p-toluenesulfonic acid, methanesulfonic acid, and tosylic acid are preferred, but not limited thereto. Among them, the free form is more preferably used.
  • suplatast or a pharmaceutically acceptable salt thereof a free form of suplatast or an acid addition salt obtained by the action of a pharmaceutically acceptable acid is preferable.
  • the acid addition salts include salts with inorganic acids such as hydrochloric acid, sulfuric acid, phosphoric acid, and hydrobromic acid; oxalic acid, maleic acid, fumaric acid, malic acid, tartaric acid, citric acid, benzoic acid, acetic acid, and the like.
  • Salts with organic acids such as lactic acid, p-toluenesulfonic acid, methanesulfonic acid, and tosylic acid are preferable, but not particularly limited thereto. Among them, tosylate is more preferably used.
  • the present invention also encompasses a pharmaceutical composition for preventing or treating a disease caused by delayed allergic reaction, comprising the component (a) and the component (b).
  • a pharmaceutical composition for preventing or treating a disease caused by delayed allergic reaction comprising the component (a) and the component (b).
  • late-onset allergic reaction refers to an allergic reaction that occurs within a few hours after the inducing substance serving as an antigen enters the body.
  • Examples of such a disease caused by late-onset allergic reaction include allergic rhinitis, bronchial asthma, allergic skin disease, allergic eye disease and the like.
  • the present invention also relates to allergic rhinitis, bronchial asthma, Pharmaceutical compositions for the prevention or treatment of luggy skin disease, allergic eye disease, acute rhinitis or sinusitis are included.
  • allergic rhinitis is a disease characterized by sneezing, runny nose, and nasal congestion resulting from an antigen-antibody reaction, and other symptoms such as nasal itching and nosebleeds.
  • Bronchial asthma is a disease characterized by airway obstruction and inflammation of the airways and having symptoms such as wheezing, coughing, dyspnea, and power sputum.
  • the “allergic skin disease” includes allergic contact dermatitis, atopic dermatitis, juniper, etc., and is a disease having symptoms such as pruritus, rash, and redness.
  • Allergic eye disease includes allergic conjunctivitis or allergic keratoconjunctivitis, spring catarrh, etc., and is a disease mainly caused by pruritus, conjunctival congestion, and lacrimation.
  • Acute rhinitis is a condition in which the virus attaches to the nasal mucosa, causing inflammation in the nasal mucosa, causing sneezing, runny nose and nasal congestion.
  • Seusitis is a condition in which pus and mucus accumulate in the sinuses due to infection by bacteria, fungi, and viruses, causing nasal congestion and viscous runny nose and headache. It may be associated with rhinitis or aspirin asthma.
  • the pharmaceutical composition of the present invention provides sneezing, runny nose, nasal congestion, wheezing, cough, dyspnea, and sputum, pruritus, rash, redness, pruritus of eyes, conjunctival congestion, and blood flow, which are symptoms caused by the above-mentioned diseases. Tears and headaches due to nasal congestion are also effective.
  • the present invention also includes a pharmaceutical composition for preventing or treating nasal obstruction, comprising the component (a) and the component (b).
  • nasal congestion refers to any symptom of swelling of the nasal mucosa, accumulation of nasal secretions, or symptoms of respiratory inhalation due to nasal polyps or the like, and particularly to allergic rhinitis, acute rhinitis, and sinusitis. Causes.
  • composition of the present invention which is a combination of mequitazine and suplatast as active ingredients
  • other physiologically active ingredients can be added as required.
  • bioactive components include antipyretic analgesic and anti-inflammatory drugs, antihistamines, antitussives or bronchodilators, sputum dissolving agents, central stimulants, anticholinergics, chemical mediator release inhibitors, Th2 sites Inhibitors, leukotriene receptor antagonists, thromboxane A2 receptor antagonists, vitamins, antacids, crude drugs, herbal prescriptions, etc., but are not limited to these. Yes. Also, it can be used as a cold medicine mixed with these physiologically active ingredients.
  • the pharmaceutical composition of the present invention is usually administered in one or more divided doses per day, and the dose may be appropriately adjusted depending on the age, body weight, symptoms and administration form of the patient.
  • the daily dose for an adult is usually 0.5 to 24 mg, preferably 1.0 to 12 mg for mequitazine, 30 to 60 mg for splatast, and preferably 50 to 300 mg for suplatast.
  • the mixing ratio of mequitadine to supratast is preferably 3 to 300 parts by weight S, more preferably 5 to 150 parts by weight, and particularly preferably 10 to 100 parts by weight with respect to 1 part by weight of mequitazine.
  • the effect of the present invention will not be sufficiently exhibited, and if it exceeds 300 parts by weight, an effect corresponding to the amount of splatast will not be obtained.
  • the pharmaceutical composition of the present invention includes tablets, pills, capsules, granules, fine granules, powders, chewables, foaming agents, drops, mouth dissolving agents, dry syrups, dispersants, and jellies. It can be used in any form such as oral forms such as internal liquids, nasal drops, eye drops, external preparations and injections. These preparations can be manufactured by a conventional method, and any additives can be used as long as they are used for usual drug production. Specific examples are shown below, but the present invention is not limited to these.
  • Ingredients that can be used in the preparation of a solid preparation include core substances such as sucrose granules, sucrose 'corn starch mixed granules, crystalline cellulose granules, and lactose' crystalline cellulose mixed granules; lactose, starch Excipients such as sucrose, mannitol, crystalline cellulose, etc .; Binders; disintegrators such as carboxymethylcellulose calcium, polybutylpyrrolidone or its crosslinked product, and low-substituted hydroxypropylcellulose; nonionic surfactants such as sucrose fatty acid esters and polyoxysorbitan fatty acid esters; calcium stearate , Magnesium stearate, dimme Le polysiloxanes, talc, corn starch, polyethylene glycol, lubricants may be mentioned, such as hydrogenated oil, a coloring agent, if other necessary, Chi possible to use such sweeteners.
  • core substances such as sucrose granul
  • the solid preparation can be coated as necessary.
  • Coating agents include ethyl cellulose, Eudragit, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose 'acetate' succinate, methacrylic acid, methyl methacrylate copolymer, cellulose 'acetate' phthalate, polybutylpyrrolidone, polyethylene glycol, shellac , Methylcellulose, cellulose acetate phthalate and the like.
  • Solid preparations can be sugar-coated with sucrose, acacia, calcium carbonate, talc, gelatin and the like as the main component.
  • Ingredients that can be used in the preparation of the liquid preparation include purified water, ethanol, glycerin, sucrose, propylene glycol, polyethylene glycol, polyoxyethylene sorbitan fatty acid ester, metahydroxy sodium hydroxide, agar, and tragacanth gum. No.
  • a solubilizer, a buffer, a preservative, a flavor, a coloring agent, a flavoring agent, and the like can be used.
  • the pharmaceutical composition of the present invention can be used for prevention or treatment of a disease caused by delayed allergic reaction. Further, the pharmaceutical composition of the present invention can be used for prevention or treatment of diseases such as allergic rhinitis, bronchial asthma, allergic skin disease, allergic eye disease, acute rhinitis and sinusitis. Still further, the pharmaceutical composition of the present invention can be used for prevention or treatment of nasal obstruction.
  • diseases such as allergic rhinitis, bronchial asthma, allergic skin disease, allergic eye disease, acute rhinitis and sinusitis.
  • the pharmaceutical composition of the present invention can be used for prevention or treatment of nasal obstruction.
  • the pharmaceutical composition of the present invention includes a preparation containing mequitazine or a pharmaceutically acceptable salt thereof as an active ingredient and a preparation containing suplatast or a pharmaceutically acceptable salt thereof as an active ingredient. Each of them can be prepared and used in combination.
  • the dosage forms of both preparations may be the same or different, and the administration of both preparations may be simultaneous, at a predetermined time interval. There may be.
  • the component (a) and the component (b) are in the form of separate preparations, for example, a tablet containing the component (a) and a capsule containing the component (b) are produced. Then, these can be used in combination.
  • the capsules were prepared at the above mixing ratio according to a conventional method.
  • a dry syrup was prepared at the above-mentioned mixing ratio according to a conventional method. This dry syrup can be used by suspending it in water before use.
  • Capsules were prepared in the above proportions according to a conventional method.
  • Titanium dioxide 2.0 m
  • Test Example 1 Inhibitory effect of delayed allergic reaction
  • test drug was dissolved or suspended in a 0.5% hydroxypropylmethylcellulose (HPMC) solution and orally administered 1 hour before the induction of the reaction.
  • HPMC hydroxypropylmethylcellulose
  • Fig. 14 shows the combined effect of the combination of the antihistamine used in this study and sublatast tosilate on the delayed ear edema reaction.
  • the normal group is a group in which the ear edema reaction was not induced
  • the control group is a group in which the ear edema reaction was induced, and then the test compound was dissolved.
  • Vehicle (0.5% HPMC) was administered.
  • the ED value which is an amount of a drug effective to reduce ear edema by 50%, was calculated.
  • the ED value after administration of mequitazine alone was 16.9 mg / kg
  • mequitazine and suplatast tosylate enhanced the delayed allergic reaction inhibitory effect. From this, it is possible to reduce the dose of mequitazine by using it in combination with suplatast tosilate, and it can be expected that side effects are reduced.
  • Test Example 2 Examination of guinea pig antigen-induced delayed nasal cavity resistance
  • nRaw nasal airway resistance
  • AUC area under the curve
  • AUC 1/2 (I +2 X 1 +2 X 1 +2 X 1 +1) [0037]
  • the drug was repeatedly orally administered once a day for 15 days from the nasal sensitization one week after the first sensitization to the induction day three weeks after the first sensitization. On the day of nasal sensitization (one week and two weeks after the first sensitization) and on the day of induction, the drug was orally administered 1 hour before intranasal administration of ovalbumin. Mequitazine and sublatast tosilate were used as test drugs, and prednisolone, which is commonly used for severe late-onset allergic disease, was used as a positive control substance.

Abstract

L'invention porte sur une composition médicinale dont les effets potentialisés permettent d'améliorer divers symptômes tels que la rhinite allergique, l'asthme bronchique, la dermatite allergique, les maladies oculaires allergiques, la rhinite aiguë et la sinusite. L'invention porte notamment sur une composition médicinale comprenant une combinaison de (a) méquitazine ou son sel acceptable d'un point de vue pharmaceutique avec (b) suplatast ou son sel acceptable d'un point de vue pharmaceutique, cette composition ayant d'excellents effets dans l'amélioration de divers symptômes tels que la rhinite allergique, l'asthme bronchique, la dermatite allergique, les maladies oculaires allergiques, la rhinite aiguë et la sinusite.
PCT/JP2004/019227 2003-12-26 2004-12-22 Composition medicinale pour le traitement de symptomes allergiques WO2005063253A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2005516607A JPWO2005063253A1 (ja) 2003-12-26 2004-12-22 アレルギー症状治療用医薬組成物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003-435105 2003-12-26
JP2003435105 2003-12-26

Publications (1)

Publication Number Publication Date
WO2005063253A1 true WO2005063253A1 (fr) 2005-07-14

Family

ID=34736590

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2004/019227 WO2005063253A1 (fr) 2003-12-26 2004-12-22 Composition medicinale pour le traitement de symptomes allergiques

Country Status (3)

Country Link
JP (1) JPWO2005063253A1 (fr)
TW (1) TW200533361A (fr)
WO (1) WO2005063253A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2924344A1 (fr) * 2007-12-04 2009-06-05 Pierre Fabre Medicament Sa Utilisation de la mequitazine sous la forme de racemate ou d'enantiomeres pour la preparation d'un medicament destine au traitement ou a la prevention de pathologies impliquant les recepteurs histaminiques h4.
WO2009122182A1 (fr) * 2008-04-04 2009-10-08 Cardoz Ab Nouvelle combinaison destinée au traitement de troubles inflammatoires
WO2009122183A1 (fr) * 2008-04-04 2009-10-08 Cardoz Ab Nouvelle combinaison destinée au traitement de troubles inflammatoires
US9916136B2 (en) 2008-12-29 2018-03-13 Microsoft Technology Licensing, Llc Interface infrastructure for a continuation based runtime

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0725758A (ja) * 1993-05-14 1995-01-27 Taiho Yakuhin Kogyo Kk 眼局所抗アレルギー剤
WO1996033741A1 (fr) * 1995-04-24 1996-10-31 Taiho Pharmaceutical Co., Ltd. Remede pour maladies allergiques, a appliquer dans la region du nez
JP2000086533A (ja) * 1998-09-17 2000-03-28 Fuji Chemical Industries Ltd 新規なアレルギー治療剤

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0725758A (ja) * 1993-05-14 1995-01-27 Taiho Yakuhin Kogyo Kk 眼局所抗アレルギー剤
WO1996033741A1 (fr) * 1995-04-24 1996-10-31 Taiho Pharmaceutical Co., Ltd. Remede pour maladies allergiques, a appliquer dans la region du nez
JP2000086533A (ja) * 1998-09-17 2000-03-28 Fuji Chemical Industries Ltd 新規なアレルギー治療剤

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
INAGAKI N. ET AL: "Characterization of Anthihistamines Using Biphasic Cutaneous Reaction in BALB/c mice", LIFE SCIENCES, vol. 63, no. 11, 1998, pages PL145 - PL150, XP002985982 *
SATOH T. ET AL: "Suplatast tosilate inhibits eosinophil production and recruitment into the skin in murine contact sensitivity", CLINICAL IMMUNOLOGY, vol. 108, September 2003 (2003-09-01), pages 257 - 262, XP002985983 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2924344A1 (fr) * 2007-12-04 2009-06-05 Pierre Fabre Medicament Sa Utilisation de la mequitazine sous la forme de racemate ou d'enantiomeres pour la preparation d'un medicament destine au traitement ou a la prevention de pathologies impliquant les recepteurs histaminiques h4.
FR2924345A1 (fr) * 2007-12-04 2009-06-05 Pierre Fabre Medicament Sa Utilisation de la mequitazine sous la forme de racemate ou d'enantiomeres pour la preparation d'un medicament destine au traitement ou a la prevention de pathologies impliquant les recepteurs histaminiques h4.
WO2009071625A1 (fr) * 2007-12-04 2009-06-11 Pierre Fabre Medicament Utilisation de méquitazine sous sa forme racémate ou énantiomère dans la préparation d'un médicament destiné à traiter ou à prévenir les pathologies impliquant les récepteurs h4 de l'histamine
EP2255811A1 (fr) * 2007-12-04 2010-12-01 Pierre Fabre Medicament Méquitazine pour traiter ou prévenir les pathologies impliquant les récepteurs histaminiques H4
CN101883566B (zh) * 2007-12-04 2013-03-06 皮埃尔法布雷医药公司 用于治疗或预防涉及组胺h4受体的病症的美喹他嗪
RU2510273C2 (ru) * 2007-12-04 2014-03-27 Пьер Фабр Медикамент Меквитазин для лечения или предотвращения патологий, в которых задействованы н4 рецепторы гистамина
AU2008333220B2 (en) * 2007-12-04 2014-04-24 Pierre Fabre Medicament Mequitazine for treating or preventing pathologies involving histamine H4 receptors
WO2009122182A1 (fr) * 2008-04-04 2009-10-08 Cardoz Ab Nouvelle combinaison destinée au traitement de troubles inflammatoires
WO2009122183A1 (fr) * 2008-04-04 2009-10-08 Cardoz Ab Nouvelle combinaison destinée au traitement de troubles inflammatoires
US9916136B2 (en) 2008-12-29 2018-03-13 Microsoft Technology Licensing, Llc Interface infrastructure for a continuation based runtime

Also Published As

Publication number Publication date
TW200533361A (en) 2005-10-16
JPWO2005063253A1 (ja) 2007-12-13

Similar Documents

Publication Publication Date Title
JP5241228B2 (ja) 非ステロイド性抗炎症薬、鬱血除去薬および鎮静作用の少ない抗ヒスタミン薬を含む多層錠
JP6226916B2 (ja) 医薬組成物
EP2799071B1 (fr) Lévocétirizine et montélukast pour le traitement de la grippe et le rhume
JP2001517639A (ja) 鼻炎／結膜炎および感冒、感冒に似た症状および／または流行性感冒の症状を局所的に治療するための、鎮静作用を有しない抗ヒスタミンおよびα−アドレナリン作動薬を含む組合せ物の使用
JP2003522803A (ja) 鼻炎／結膜炎の治療のために、ロイコトリエンの作用に影響する物質による非鎮静抗ヒスタミン薬の新規な組み合わせ
WO2005094832A1 (fr) Compositions contenant du meloxicame
US20200101067A1 (en) Use of levocetirizine and montelukast in the treatment of anaphylaxis
AU2014249534B2 (en) Use of levocetirizine and montelukast in the treatment of vasculitis
EP1572206B1 (fr) Compositions de medicaments anti-inflammatoires non-steroidaux, decongestionnants et antihistaminiques
AU2008259864B2 (en) Methods and compositions for administration of Oxybutynin
US8748488B2 (en) Methods and compositions for administration of oxybutynin
US20050038018A1 (en) Meloxicam compositions
WO2005063253A1 (fr) Composition medicinale pour le traitement de symptomes allergiques
TW202317101A (zh) 治療抑鬱狀態之方法
JP4384435B2 (ja) くしゃみ抑制組成物
TW200838524A (en) Methods for treating nasal congestion in hepatically impaired patients
JP3428465B2 (ja) 新規な抗アレルギー抗炎症組成物
JP2004002353A (ja) 医薬組成物
JPWO2004039408A1 (ja) 医薬組成物
WO2002047689A2 (fr) Methode pour empecher l'urticaire
TW200838534A (en) Treatment for irritable bowel syndrome
JP2004175786A (ja) Ｉ型アレルギー疾患治療用組成物

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005516607

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase